Merck Quick Ratio 2010-2022 | MRK

Historical quick ratio values for Merck (MRK) over the last 10 years.
Merck Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-06-30 $26.58B $23.17B 1.15
2022-03-31 $25.41B $22.32B 1.14
2021-12-31 $24.31B $23.87B 1.02
2021-09-30 $25.46B $23.73B 1.07
2021-06-30 $23.17B $21.91B 1.06
2021-03-31 $20.51B $26.36B 0.78
2020-12-31 $22.21B $27.33B 0.81
2020-09-30 $20.45B $20.41B 1.00
2020-06-30 $23.29B $22.18B 1.05
2020-03-31 $20.33B $23.48B 0.87
2019-12-31 $21.51B $22.22B 0.97
2019-09-30 $20.29B $20.68B 0.98
2019-06-30 $18.45B $20.09B 0.92
2019-03-31 $19.64B $18.54B 1.06
2018-12-31 $20.44B $22.21B 0.92
2018-09-30 $21.42B $18.59B 1.15
2018-06-30 $18.89B $18.13B 1.04
2018-03-31 $18.70B $16.96B 1.10
2017-12-31 $19.67B $18.61B 1.06
2017-09-30 $22.66B $19.47B 1.16
2017-06-30 $22.76B $18.76B 1.21
2017-03-31 $26.38B $19.82B 1.33
2016-12-31 $25.75B $17.20B 1.50
2016-09-30 $24.20B $15.56B 1.56
2016-06-30 $22.68B $14.92B 1.52
2016-03-31 $23.67B $17.57B 1.35
2015-12-31 $25.05B $19.20B 1.31
2015-09-30 $23.44B $17.58B 1.33
2015-06-30 $23.01B $17.51B 1.31
2015-03-31 $27.39B $20.44B 1.34
2014-12-31 $27.03B $18.40B 1.47
2014-09-30 $28.90B $25.93B 1.12
2014-06-30 $27.45B $17.93B 1.53
2014-03-31 $34.86B $22.47B 1.55
2013-12-31 $29.46B $17.87B 1.65
2013-09-30 $31.02B $18.22B 1.70
2013-06-30 $30.23B $18.40B 1.64
2013-03-31 $28.47B $18.80B 1.51
2012-12-31 $28.32B $18.35B 1.54
2012-09-30 $29.50B $15.58B 1.89
2012-06-30 $29.39B $16.91B 1.74
2012-03-31 $28.01B $16.58B 1.69
2011-12-31 $26.93B $16.25B 1.66
2011-09-30 $27.87B $16.59B 1.68
2011-06-30 $26.14B $15.76B 1.66
2011-03-31 $24.97B $15.66B 1.59
2010-12-31 $23.20B $15.64B 1.48
2010-09-30 $21.49B $17.32B 1.24
2010-06-30 $20.01B $15.42B 1.30
2010-03-31 $21.42B $16.46B 1.30
2009-12-31 $20.38B $15.64B 1.30
2009-09-30 $27.57B $8.03B 3.44
2009-06-30 $27.08B $11.51B 2.35
2009-03-31 $24.06B $13.42B 1.79
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.318B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Pfizer (PFE) United States $245.989B 7.21
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17